Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD UCSF
Dates
study started
estimated completion

Description

Summary

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

Official Title

A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Keywords

Non-Small Cell Lung Cancer Colorectal Cancer Advanced Solid Tumors KRAS G12C GDC-6036 Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms

Eligibility

You can join if…

Open to people ages 18 years and up

  • Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.

You CAN'T join if...

  • Active brain metastases.
  • Malabsorption or other condition that interferes with enteral absorption.
  • Clinically significant cardiovascular dysfunction or liver disease.

Locations

  • UCSD Moores Cancer Center not yet accepting patients
    La Jolla California 92093 United States
  • Univ of Calif, San Francisco; Breast Cancer Center not yet accepting patients
    San Francisco California 94115 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Genentech, Inc.
ID
NCT04449874
Phase
Phase 1
Study Type
Interventional
Last Updated